ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly net cash provided by operating activities ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Cash Flows (Postgres DB)
Latest, FY2025
16,813
Period ended Dec 31, 2025
Change on a year earlier
+90.7%
8,818 in FY2024
History
19 years
Since FY2007
Sources
12
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net cash provided by operating activities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 16,813 | +90.7% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 8,818 | +108.0% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 4,240 | -44.1% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | 7,586 | +3.0% | Form 10-K (filed 2024-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 7,366 | +13.3% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 6,500 | +34.4% | Form 10-K (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 4,837 | -12.5% | Form 10-K (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 5,525 | -1.6% | Form 10-K (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 5,616 | +15.8% | Form 10-K (filed 2018-02-20) ↗ |
| FY2016 | Dec 31, 2016 | 4,851 | +63.6% | Form 10-K (filed 2017-02-21) ↗ |
| FY2015 | Dec 31, 2015 | 2,965 | -33.5% | Form 10-K (filed 2017-02-21) ↗ |
| FY2014 | Dec 31, 2014 | 4,458 | -22.3% | Form 10-K (filed 2017-02-21) ↗ |
| FY2013 | Dec 31, 2013 | 5,735 | +8.1% | Form 10-K (filed 2014-02-19) ↗ |
| FY2012 | Dec 31, 2012 | 5,305 | -26.7% | Form 10-K (filed 2013-02-21) ↗ |
| FY2011 | Dec 31, 2011 | 7,235 | +5.5% | Form 10-K (filed 2012-02-24) ↗ |
| FY2010 | Dec 31, 2010 | 6,857 | +58.2% | Form 10-K (filed 2011-02-22) ↗ |
| FY2009 | Dec 31, 2009 | 4,336 | -40.6% | Form 10-K (filed 2010-02-22) ↗ |
| FY2008 | Dec 31, 2008 | 7,296 | +41.5% | Form 10-K (filed 2010-02-22) ↗ |
| FY2007 | Dec 31, 2007 | 5,155 | – | Form 10-K (filed 2010-02-22) ↗ |
Breakdown
What makes up net cash provided by operating activities ($m)
- Depreciation and amortization ($M)1,997 · FY2025
- Stock-based compensation expense ($M)626 · FY2025
- Deferred income taxes ($M)-1,707 · FY2025
- Change in receivables ($M)-7,000 · FY2025
- Change in inventories ($M)-4,671 · FY2025
- Change in accounts payable and other liabilities ($M)10,187 · FY2025
- Net cash used for investing activities ($M)-10,972 · FY2025
- Net cash provided by / (used for) financing activities ($M)-2,213 · FY2025
- Effect of exchange rate changes on cash and equivalents ($M)372 · FY2025
- Net increase / (decrease) in cash and cash equivalents ($M)4,000 · FY2025
Cite this data
StockData. (2026). Eli Lilly Net cash provided by operating activities ($M) ($M), annual FY2007–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/fin_ocf
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.